Aeglea BioTherapeutics Appoints Jeffrey M. Goldberg as Chief Executive Officer

AUSTIN, Texas, Nov. 30, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced the appointment of Jeffrey M....